Benevolent News Hub

In the media
News
BenevolentAI’s platform-derived hypothesis for COVID-19 treatment validated in US NIAID randomised control trial
NIAID trial shows baricitinib in combination with remdesivir reduces the recovery time in patients hospitalised with COVID-19, validating BenevolentAI’s AI-derived hypothesis.
Sep 14, 2020
Blog
Building the next generation of leaders with Circl
BenevolentAI Director of Talent Acquisition and Development, Yasmina Rahiman, explores the power of coaching for leadership development in technology.
Aug 21, 2020
News
Clinical data validates BenevolentAI's AI predicted hypothesis for baricitinib as a potential treatment for COVID-19
Research published in EMBO Molecular Medicine confirms AI predictions for anti-viral and anti-cytokine signalling effects of baricitinib in critically hospitalised COVID-19 patients
Jul 1, 2020
News
COVID-19 and AI: An editorial review in EMBO from Michael B. Schultz, Daniel Vera, David A. Sinclair
David Sinclair and colleagues review our recent publication in the EMBO Molecular Medicine Journal in support of our AI-derived hypothesis for a potential treatment of COVID-19.
Jul 1, 2020
Video
How do we get the next 10 years right? w/ Joanna Shields, CogX
“We need leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all". Our CEO Joanna Shields opens CogX 2020 sharing inspiration for the next decade.
Jun 8, 2020
Blog
Kindness matters: mental health and wellbeing through COVID-19 and beyond
To conclude Mental Health awareness week, we share some thoughts about the power of kindness and how building a culture of openness will help shape the future of business.
May 27, 2020
Blog
Yoga and mental health: a conversation between two professional scientists and professional yogis
For Mental Health Awareness Week, BenevolentAI’s in-house yogis and bioinformaticians evaluated the scientific research behind the effect of yoga on mental health.
May 20, 2020
News
Potential treatment for COVID-19 identified by BenevolentAI enters randomised clinical trial
BenevolentAI announced that baricitinib is entering clinical testing as a potential COVID-19 treatment. Benevolent identified the drug using its AI drug discovery platform. The trial by Eli Lilly will investigate the drug’s efficacy and safety.
Apr 10, 2020
Blog
Future Fifty: joining forces to drive forward positive change
BenevolentAI today announced it has been selected for Tech Nation’s 2020 Future Fifty cohort. Our CEO Joanna Shields reflects on how joining forces with like-minded industry experts can serve as a powerful vehicle for transformation.
Mar 17, 2020
Video
Challenges of designing an AI platform for Drug Discovery w/ Marek Kultys
Our Senior Product Designer explores the design process at BenevolentAI where he builds user facing tools that help our scientists discover and develop new medicines.
Mar 17, 2020